164 related articles for article (PubMed ID: 26087110)
1. A sustained intravitreal drug delivery system with remote real time monitoring capability.
Hou H; Nieto A; Belghith A; Nan K; Li Y; Freeman WR; Sailor MJ; Cheng L
Acta Biomater; 2015 Sep; 24():309-21. PubMed ID: 26087110
[TBL] [Abstract][Full Text] [Related]
2. Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.
Hou H; Wang C; Nan K; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):557-66. PubMed ID: 26882530
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.
Wang C; Hou H; Nan K; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2014 Dec; 129():74-82. PubMed ID: 25446320
[TBL] [Abstract][Full Text] [Related]
4. Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.
Nieto A; Hou H; Moon SW; Sailor MJ; Freeman WR; Cheng L
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1070-80. PubMed ID: 25613937
[TBL] [Abstract][Full Text] [Related]
5. Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.
Hou H; Nieto A; Ma F; Freeman WR; Sailor MJ; Cheng L
J Control Release; 2014 Mar; 178():46-54. PubMed ID: 24424270
[TBL] [Abstract][Full Text] [Related]
6. Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.
Warther D; Xiao Y; Li F; Wang Y; Huffman K; Freeman WR; Sailor M; Cheng L
Drug Deliv; 2018 Nov; 25(1):1537-1545. PubMed ID: 29996687
[TBL] [Abstract][Full Text] [Related]
7. Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.
Hartmann KI; Nieto A; Wu EC; Freeman WR; Kim JS; Chhablani J; Sailor MJ; Cheng L
J Ocul Pharmacol Ther; 2013 Jun; 29(5):493-500. PubMed ID: 23448595
[TBL] [Abstract][Full Text] [Related]
8. Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.
Chhablani J; Nieto A; Hou H; Wu EC; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1268-79. PubMed ID: 23322571
[TBL] [Abstract][Full Text] [Related]
9. Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles.
Wu EC; Andrew JS; Cheng L; Freeman WR; Pearson L; Sailor MJ
Biomaterials; 2011 Mar; 32(7):1957-66. PubMed ID: 21122914
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle.
Cheng L; Anglin E; Cunin F; Kim D; Sailor MJ; Falkenstein I; Tammewar A; Freeman WR
Br J Ophthalmol; 2008 May; 92(5):705-11. PubMed ID: 18441177
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of degradation of porous silicon photonic crystals using digital photography.
Ariza-Avidad M; Nieto A; Salinas-Castillo A; Capitan-Vallvey LF; Miskelly GM; Sailor MJ
Nanoscale Res Lett; 2014; 9(1):410. PubMed ID: 25242902
[TBL] [Abstract][Full Text] [Related]
12. Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles.
Nieto A; Hou H; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2013 Nov; 116():161-8. PubMed ID: 24036388
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity assessment of porous silicon microparticles for ocular drug delivery.
Korhonen E; Rönkkö S; Hillebrand S; Riikonen J; Xu W; Järvinen K; Lehto VP; Kauppinen A
Eur J Pharm Biopharm; 2016 Mar; 100():1-8. PubMed ID: 26686646
[TBL] [Abstract][Full Text] [Related]
14. A sustained dual drug delivery system for proliferative vitreoretinopathy.
Xiao Y; Choi KS; Warther D; Huffman K; Landeros S; Freeman WR; Sailor MJ; Cheng L
Drug Deliv; 2020 Dec; 27(1):1461-1473. PubMed ID: 33100053
[TBL] [Abstract][Full Text] [Related]
15. Oxidation-Induced Trapping of Drugs in Porous Silicon Microparticles.
Fry NL; Boss GR; Sailor MJ
Chem Mater; 2014 Apr; 26(8):2758-2764. PubMed ID: 25678746
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic and clinical profile of dexamethasone intravitreal implant.
Robinson MR; Whitcup SM
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):629-47. PubMed ID: 23234323
[TBL] [Abstract][Full Text] [Related]
17. A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.
Hou H; Huffman K; Rios S; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2755-63. PubMed ID: 25829415
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional poly(lactic-co-glycolic acid)/silica colloidal crystal microparticles for sustained drug release and visualized monitoring.
Guo R; Sun XT; Zhang Y; Wang DN; Yang CG; Xu ZR
J Colloid Interface Sci; 2018 Nov; 530():465-472. PubMed ID: 29990782
[TBL] [Abstract][Full Text] [Related]
19. Release of functional dexamethasone by intracellular enzymes: A modular peptide-based strategy for ocular drug delivery.
Bhattacharya M; Sadeghi A; Sarkhel S; Hagström M; Bahrpeyma S; Toropainen E; Auriola S; Urtti A
J Control Release; 2020 Nov; 327():584-594. PubMed ID: 32911015
[TBL] [Abstract][Full Text] [Related]
20. Release and velocity of micronized dexamethasone implants with an intravitreal drug delivery system: kinematic analysis with a high-speed camera.
Meyer CH; Klein A; Alten F; Liu Z; Stanzel BV; Helb HM; Brinkmann CK
Retina; 2012; 32(10):2133-40. PubMed ID: 23060033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
